Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials.
Efforts to make vaccines against infectious diseases and immunotherapies for cancer have evolved to utilize a variety of heterologous expression systems such as viral vectors. These vectors are often attenuated or engineered to safely deliver genes encoding antigens of different pathogens. Adenovirus and poxvirus vectors are among the viral vectors that are most frequently used to develop prophylactic vaccines against infectious diseases as well as therapeutic cancer vaccines. This mini-review describes the trends and processes in large-scale production of adenovirus and poxvirus vectors to meet the needs of clinical applications. We briefly describe the general principles for the production and purification of adenovirus and poxvirus viral vectors. Currently, adenovirus and poxvirus vector manufacturing methods rely on well-established cell culture technologies. Several improvements have been evaluated to increase the yield and to reduce the overall manufacturing cost, such as cultivation at high cell densities and continuous downstream processing. Additionally, advancements in vector characterization will greatly facilitate the development of novel vectored vaccine candidates.
Laboratory of Molecular Microbiology Vaccinology and Biotechnology Development, Viral Vaccines R&D Unit. Institut Pasteur de Tunis, Tunis, Tunisia.
Héla
H
Kallel
Amine A
AA
Kamen
D000256:Adenoviridae / Q000235:genetics*; D061249:Batch Cell Culture Techniques; D002452:Cell Count; D002986:Clinical Trials as Topic; D005822:Genetic Vectors; D006801:Humans; D011212:Poxviridae / Q000235:genetics*; D014765:Viral Vaccines / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D014776:Virus Cultivation / Q000379:methods*
D014765:Viral Vaccines
Adenovirus; Clinical trials; Poxvirus; Process development; Vectored vaccines